Compare Neurocrine Biosciences Inc (NBIX) vs Tidewater Inc (TDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Tidewater Inc — how do they compare? Neurocrine Biosciences Inc trades at $142.45 (market cap $14.36B), while Tidewater Inc trades at $85.17 (market cap $4.21B). The key difference: Neurocrine Biosciences Inc is far larger — about 3.4× Tidewater Inc's market cap, and Tidewater Inc is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Tidewater Inc for 25 Days on average.
| NBIX | TDW | |
|---|---|---|
Market Cap | $14.36B | $4.21B |
Volume | 1,237,180 | 590,005 |
Sector | Health | Energy |
52-Week High | $185.50 | $100.61 |
52-Week Low | $123.10 | $47.29 |
Typical Hold Time | 23 Days | 25 Days |
Enterprise Value | $14.37B | $4.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
Tidewater (TDW) trades at $85.16, up 2.11% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with an 18.34% net margin and 19.49% ROE, though recent earnings missed expectations in Q1 and Q2 2026. The company completed the Wilson Sons Ultratug acquisition in August 2026, enhancing its offshore services footprint. Cash flow remains robust with $252.54M net cash flow in 2025.
Outlook is mixed: analyst consensus targets $105.50 (23.9% upside), but earnings volatility and competitive pressures pose risks. Institutional interest is strong, with BlackRock investing $503.20M in Q2 2026. Investors should weigh solid fundamentals against execution risks in a volatile energy market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →
